Dr. Stefano Stefano | Medicine and Health Sciences | Best Researcher Award

MD, Specializing in Rheumatology (4th year) University of Bari, Rheumatology Unit Italy

👨‍⚕️ Stefano Stano is a 4th-year MD specializing in Rheumatology at the University of Bari “Aldo Moro,” Polyclinic Hospital. His passion for rheumatology and medical research drives his active involvement in clinical and translational studies, focusing on systemic sclerosis, Sjögren’s disease, and other connective tissue disorders. Stefano aspires to pursue a Ph.D. and build an academic career contributing to advancements in rheumatology.

Profile

Orcid

Education

🎓 Stefano holds an MD and is in the final year of his specialization in Rheumatology at the University of Bari “Aldo Moro.” His academic journey is marked by consistent dedication to both theoretical and practical aspects of his field.

Experience

🩺 With over 5 years of daily involvement in research and clinical practice, Stefano balances laboratory experiments and outpatient assessments. His hands-on approach to rheumatic diseases has honed his skills in addressing complex cases and conducting in-depth studies.

Research Interests

🔬 Stefano’s research is centered on rheumatic diseases, with a special emphasis on systemic sclerosis and Sjögren’s syndrome. He is particularly interested in exploring translational approaches that bridge laboratory findings with clinical applications.

Awards

🏅 Stefano aims to secure the Best Researcher Award in recognition of his efforts in advancing rheumatological research. His dedication and achievements position him as a strong contender.

Publications Top Notes: 

📚 Stefano’s contributions to the field are evidenced by his peer-reviewed publications, which include studies on targeted therapies, systemic sclerosis, and rheumatoid arthritis. His works have been published in reputed journals:

Cacciapaglia F, et al. (2022). Comparison of Adalimumab to Other Targeted Therapies in Rheumatoid Arthritis: Results from Systematic Literature Review and Meta-Analysis. J Pers Med. Read here.

Fornaro M, et al. (2022). Prevalence and management of tuberculosis infection in Apulian rheumatologic patients treated with biologics: An observational cohort 10-year study from the BIOPURE registry. Eur J Clin Invest. Read here.

Cacciapaglia F, et al. (2022). Subcutaneous immunoglobulin therapy for refractory skin thickening in rapidly progressive systemic sclerosis: A case report and literature review. Journal of Scleroderma and Related Disorders. Read here.

De Luca G, et al. (2024). Rituximab retention rate in systemic sclerosis: a long-term real-life multicenter study. Rheumatology. Read here.

Iannone C, et al. (2024). Pulmonary and extra-pulmonary effects of lung transplantation in systemic sclerosis. Rheumatology. Read here.

De Lorenzis E, et al. (2024). Long-term retention rate, adverse event temporal patterns, and rescue treatment strategies of mycophenolate mofetil in systemic sclerosis: insights from real-life. Rheumatology. Read here.

Fornaro M, et al. (2024). Effectiveness of tapering rituximab dose in idiopathic inflammatory myopathies: Real-world data from a monocentric study. Joint Bone Spine. Read here.

Stano S, et al. (2024). Anti-aquaporin-5 and anti-poly-U-binding-factor-60kDa protein antibodies in primary Sjögren’s disease patients: Preliminary data and correlation with disease activity indices. Clin Exp Rheumatol. Read here.

Cacciapaglia F, et al. (2024). Modulation of IL-6 receptor/STAT3 downstream signaling in rheumatoid arthritis patients. Exp Mol Pathol. Read here.